OGEN News and Press, Oragenics Inc. From 08/24/22

N T-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies Intranasal administration elicits immune responses Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company ...

Oragenics (NYSE:OGEN) said Thursday it appointed director Kimberly Murphy as president and CEO effective immediately. Murphy joined OGEN's board in 2020. Most recently, Murphy served as VP of the influenza franchise and global vaccine commercialization leader at GSK, responsible for its globa...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President ...

Oragenics (NYSE:OGEN) on Tuesday announced peer-reviewed publication of a co-authored article which concluded that its intranasal COVID-19 vaccine candidate warranted further development. The Tampa, Fla.-based biotech's shares rose 3% to $0.31 in early trading. The article was publi...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and t...

Company to showcase NT-CoV2-1, a patient-friendly Covid vaccine candidate Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, today announced ...

Oragenics (NYSE:OGEN) said it had extended the current licensing and collaboration agreement with the National Research Council of Canada (NRC) to develop intranasal vaccine candidates against future COVID-19 variants. The company said the NRC technologies could allow the compa...

Agreement extends current licensing and collaboration agreement to include rapid production of intranasal vaccine candidates against future variants Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has ex...

Development stage biotech, Oragenics (OGEN -10.5%) has recorded the biggest intraday loss in a year on Friday after the company said that its financial statements contained an unqualified audit opinion with an explanatory paragraph on its ability to continue as a going concern. Under the...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on March 24, 2022 with the Securities and Exchange C...